Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00007020 · ClinicalTrials.gov registry record · Phase 3
Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid
A Phase 3 study of Adrenoleukodystrophy and Cholestasis, sponsored by Mirum Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 85
- Enrollment target
- 1
- Study location
NCT00007020 is a Phase 3 study of Adrenoleukodystrophy and Cholestasis that has completed, run by Mirum Pharmaceuticals. The registered enrollment target is 85 participants, below the 2,207-participant average among 6 other Adrenoleukodystrophy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00007020, a Phase 3 study of Adrenoleukodystrophy and Cholestasis, has completed, sponsored by Mirum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 85 participants
- Enrollment target
- 1
- Study location
Study Summary
OBJECTIVES: I. To Evaluate the therapeutic efficacy of cholic acid during provision of compassionate treatment to patients with identified inborn errors of bile acid synthesis and metabolism II. To assess the safety and tolerability of cholic acid
Conditions Studied
Interventions
- DRUG Cholic Acids
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 1992-01 |
| Est. Completion | 2009-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00007020
The ClinicalTrials.gov registry entry for NCT00007020 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,207-participant average among 6 other Adrenoleukodystrophy trials with a reported enrollment target (96% lower). The listed sponsor is Mirum Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Adrenoleukodystrophy appearing as the primary indexed condition, and to 1 intervention - of which Cholic Acids is the first listed.
NCT00007020 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00007020 about?
NCT00007020 is a clinical study titled "Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid". OBJECTIVES: I. To Evaluate the therapeutic efficacy of cholic acid during provision of compassionate treatment to patients with identified inborn errors of bile acid synthesis and metabolism II. To assess the safety and tolerability of cholic acid
What is the current status of trial NCT00007020?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 85 participants. The study started on 1992-01. Estimated completion is 2009-12.
What conditions does trial NCT00007020 study?
This clinical trial studies the following conditions: Adrenoleukodystrophy, Cholestasis, Infantile Refsum's Disease, Zellweger Syndrome, Peroxisomal Disorders.
What interventions are being tested in trial NCT00007020?
The interventions under investigation include: Cholic Acids (DRUG).
Who is sponsoring clinical trial NCT00007020?
This trial is sponsored by Mirum Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00007020 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adrenoleukodystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adrenoleukodystrophy National Registry Study
RECRUITING
-
The Myelin Disorders Biorepository Project
RECRUITING
-
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
RECRUITING · Phase 1
-
Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy
ACTIVE NOT RECRUITING · Phase 4
-
Human Placental-Derived Stem Cell Transplantation
COMPLETED · Phase 1
-
Stem Cell Transplant for Inborn Errors of Metabolism
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.